Litcius/Paper detail

CD‐sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID‐19)

Pengfei Sun, Xiaosheng Lu, Chao Xu, Yanjin Wang, Wenjuan Sun, Jianing Xi

2020Journal of Medical Virology46 citationsDOI

Abstract

Coronaviruses are common human viruses and include the severe acute respiratory syndrome coronavirus (SARS-CoV), the middle east respiratory syndrome coronavirus and the SARS-CoV-2. Coronaviruses mainly bind to transmembrane receptor proteins on the human cell membrane through spike proteins (S-proteins), thus releasing the RNA of the virus into the interior of the host cell to cause an infection. In this article, we discuss the mechanism and production of cyclodextrin-soluble angiotensin-converting enzyme 2 (CD-sACE2) inclusion compounds in the treatment of SARS-CoV-2 infections by blocking S-proteins. On the basis of the current research evidence, we believe that CD-sACE2 inclusion compounds have the potential to treat COVID-19. We hope that our article can provide a theoretical basis for later experiments.

Topics & Concepts

CoronavirusVirologyInclusion bodiesBetacoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Transmembrane proteinVirusMiddle East respiratory syndrome coronavirusMiddle East respiratory syndromeAngiotensin-converting enzyme 2Biology2019-20 coronavirus outbreakReceptorMedicineDiseaseBiochemistryRecombinant DNAGeneInfectious disease (medical specialty)PathologyOutbreakSARS-CoV-2 and COVID-19 ResearchReceptor Mechanisms and SignalingCOVID-19 Clinical Research Studies
CD‐sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID‐19) | Litcius